On a recent Monday, Saint Mark’s School welcomed students to the classroom for the first time since the Eaton fire. But it wasn’t business-as-usual. This was not the decades-old campus grounds ...

The exuberance of youth – and one youth in particular – appeared to have rubbed off on ebullient Shamrock Rovers manager Stephen Bradley when he reflected on his side's fantastic 1-0 win over ...

Royalty Pharma (RPRX) announced that it has entered into an agreement with Biogen (BIIB) to provide research and development funding of up to $250M for litifilimab, a first-in-class ...

Selkirk Pharma, Inc., a privately held U.S. pharmaceutical manufacturer specializing in the fill and finish of injectable drugs, including vaccines and biological therapeutics, today announced the ...

OKYO Pharma (OKYO) announces that its lead asset, OK-101, has been officially assigned the United States Adopted Name, USAN, “urcosimod”. Gary Jacob, Ph.D., Chief Executive Officer of Okyo Pha ...

DOC Pharma strengthens its offerings with the acquisition of the Geopharma nutraceuticals portfolio, and the closing of the previously announced acquisition of Muscoril® New brand identity ...

MILAN, Feb. 12, 2025 /PRNewswire/ -- DOC, an Italian pharmaceutical company specialized in the marketing of generic drugs, expands its strategy by broadening its business lines and defines a new ...

Nvidia exited its positions in several AI stocks in Q4, but maintained its stake in Recursion Pharmaceuticals. Many investors seemed to view this as a vote of confidence from Nvidia for Recursion.

- Expected use of approximately $25 million in first quarter of 2025 intended to preserve approximately 200,000 ADSs held as treasury shares COPENHAGEN, Denmark, Feb. 12, 2025 (GLOBE NEWSWIRE) -- ...

– Expected use of approximately $25 million in first quarter of 2025 intended to preserve approximately 200,000 ADSs held as treasury shares COPENHAGEN, Denmark, Feb. 12, 2025 (GLOBE NEWSWIRE ...

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, SKYTROFA®, and YORVIPATH® are trademarks owned by the Ascendis Pharma group.

The Company had approximately $98.8 million in cash and cash equivalents as of December 31, 2024. Net cash used in operating activities was approximately $60.9 million, compared to $102.0 million ...